Medical Dressing Biocompatibility Testing: Standards, Sample Preparation, Test Methods, and Regulato

Biocompatibility testing is an essential safety evaluation step for medical dressings such as gauze, hydrocolloid, foam, alginate, hydrogel, film, and antimicrobial wound care products. Performed in accordance with the ISO 10993 series of standards (and the equivalent GB/T 16886 series in China), these tests assess cytotoxicity, sensitization, irritation, systemic toxicity, and hemocompatibility to demonstrate that dressing materials are safe for their intended clinical use. This technical guide explains the applicable standards, sample preparation requirements, core testing items, test methods, and typical regulatory applications of medical dressing biocompatibility evaluation.

Technical Overview

Medical dressings are medical devices intended to cover wounds, absorb exudate, maintain a moist healing environment, and protect the wound bed from contamination. Product families include traditional gauze and nonwoven pads, transparent film dressings, hydrocolloids, hydrogels, alginates and other gel-forming fibers, polyurethane and silicone foams, silicone adhesive sheets, and antimicrobial dressings incorporating silver, iodine, polyhexamethylene biguanide (PHMB), or medical-grade honey. Depending on the design, a dressing may contact intact skin, breached or compromised skin, or open bleeding wounds for periods ranging from hours to several weeks.

Because these products interact directly with living tissue, biological safety must be demonstrated through a risk-based biocompatibility evaluation as defined in ISO 10993-1, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. The evaluation begins with characterization of the materials, additives, process residues, and sterilization method, followed by selection of biological endpoints based on the nature and duration of tissue contact: limited contact (up to 24 hours), prolonged contact (24 hours to 30 days), or permanent contact (more than 30 days). For a typical surface-contacting dressing applied to breached skin, the core endpoints are cytotoxicity, sensitization, and irritation; prolonged-contact and blood-contacting products may additionally require systemic toxicity, material-mediated pyrogenicity, subacute toxicity, genotoxicity, and hemocompatibility testing.

Biocompatibility data support regulatory submissions worldwide, including CE marking under the EU Medical Device Regulation (EU) 2017/745, premarket notification 510(k) submissions to the US FDA reviewed under the agency's ISO 10993-1 guidance, registration with China's NMPA under the GB/T 16886 series (the Chinese adoption of ISO 10993), and submissions to Japanese and other national authorities. Testing is typically performed by accredited third-party laboratories under GLP conditions where applicable, with animal studies designed according to ISO 10993-2 (Animal welfare requirements) and the 3Rs principles of replacement, reduction, and refinement. The overall biological safety evaluation is documented within the manufacturer's risk management file under ISO 14971.

Testing Samples

Finished Sterile Products

The preferred test article is the final dressing in its sterilized, ready-to-use condition, taken from representative production lots and tested within its shelf life. Testing the finished product captures the combined biological effects of all constituents, including the wound-contact layer, absorbent core, backing film, adhesives, process residues, and sterilization by-products such as ethylene oxide residues, which are separately evaluated under ISO 10993-7 when applicable.

Material Extracts

Most in vitro and in vivo tests are performed on aqueous and non-aqueous extracts prepared according to ISO 10993-12, Sample preparation and reference materials. Standard extraction vehicles include polar media such as water, physiological saline, and cell culture medium (with or without serum), and non-polar media such as sesame oil. Extraction ratios are typically 3 cm²/mL for film- and membrane-like materials or 0.2 g/mL for absorbent materials, gels, and hydrogels. Extraction conditions are selected to exaggerate but not distort clinical exposure — commonly 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour — depending on the thermal stability of the material and the intended use conditions of the dressing.

Components and Candidate Materials

During product development, individual components such as alginates, collagen, chitosan, silicone gels, polyurethane films, hydrocolloid adhesives, and antimicrobial agents are tested separately to screen formulations, compare suppliers, and support material substitutions. Component-level data are also valuable for change control when a raw material supplier or manufacturing process is modified after market launch.

Sample Quantity and Handling

Typical sample requirements are approximately 3 to 10 sterile dressings or equivalent coupons for cytotoxicity testing, 10 to 30 units for irritation and sensitization studies depending on the method, and similar quantities for systemic toxicity studies. Samples should be shipped in their original sterile packaging, accompanied by certificates of sterilization, material composition information, lot numbers, and shelf-life data, so that the laboratory can accurately identify the test article and calculate extraction ratios.

Testing Items

The biological endpoints selected for a medical dressing depend on its tissue contact classification and contact duration. The following items represent the core battery for most wound dressings:

• In vitro cytotoxicity (ISO 10993-5) — evaluates the release of substances toxic to mammalian cells; required for essentially all dressings.
• Skin sensitization (ISO 10993-10) — detects the potential to induce delayed-type hypersensitivity; required for all skin-contacting and wound-contacting dressings.
• Skin irritation and intracutaneous reactivity (ISO 10993-23) — assesses the potential to cause local inflammatory responses at intact or breached skin, or after intracutaneous injection of extracts.
• Acute systemic toxicity (ISO 10993-11) — required for prolonged-contact dressings or products applied over large body surface areas.
• Hemocompatibility (ISO 10993-4) — including hemolysis testing, frequently aligned with ASTM F756, for dressings intended for bleeding wounds or heavily exuding wound beds.
• Genotoxicity (ISO 10993-3) — Ames bacterial reverse mutation assay plus chromosomal aberration or micronucleus testing, typically for prolonged or permanent contact products and for materials with insufficient characterization data.
• Subacute and subchronic toxicity (ISO 10993-11) — for dressings in contact with breached skin for extended periods or covering large wound areas.
• Material-mediated pyrogenicity — evaluated within systemic toxicity testing or through chemical characterization.
• Chemical characterization and toxicological risk assessment (ISO 10993-18 and ISO 10993-17) — identification and safety evaluation of extractables and leachables, including monomers, plasticizers, antioxidants, adhesive residues, and antimicrobial agents.
• Ethylene oxide residue testing (ISO 10993-7) — for dressings sterilized with ethylene oxide.

Testing Methods

Cytotoxicity Testing

Cytotoxicity is evaluated according to ISO 10993-5, most commonly using the extract (elution) method with mammalian fibroblast cultures such as L929 cells. Dressing extracts are prepared in culture medium at 37°C for 24 hours and applied to cell monolayers for 24 to 48 hours. Cell viability is quantified using colorimetric assays such as MTT or neutral red uptake, and cell morphology is scored microscopically. A cell viability of 70% or greater relative to the negative control indicates the sample is non-cytotoxic under the 2009 version of the standard. Direct contact and agar diffusion (indirect contact) methods are also applied to specific geometries such as hydrogels and thin films.

Skin Sensitization Testing

Sensitization potential is assessed under ISO 10993-10 using either the guinea pig maximization test (GPMT) or the murine local lymph node assay (LLNA, OECD TG 429). The LLNA measures lymphocyte proliferation in draining lymph nodes after repeated exposure to polar and non-polar extracts and is now the preferred in vivo method because it reduces animal numbers and distress. Non-animal defined approaches combining the direct peptide reactivity assay (OECD TG 442C), keratinocyte activation assays (OECD TG 442D), and dendritic cell activation assays such as the human cell line activation test (OECD TG 442E) are increasingly accepted for certain device categories, subject to regulatory agreement.

Skin Irritation and Intracutaneous Reactivity

Since 2021, irritation testing has been governed by ISO 10993-23, which replaced the irritation requirements formerly located in ISO 10993-10. The current standard strongly favors non-animal methods: reconstructed human epidermis (RhE) models, validated under OECD TG 431 and OECD TG 439, expose three-dimensional human epidermis tissue to dressings or extracts and classify irritancy based on tissue viability. Where chemical characterization or RhE results are inconclusive, the rabbit intracutaneous reactivity test using polar and non-polar extracts remains the historical fallback method.

Systemic Toxicity and Hemocompatibility

Acute systemic toxicity is evaluated per ISO 10993-11 by administering polar and non-polar extracts intravenously and intraperitoneally to mice, followed by observation for 72 hours for signs of toxicity, body weight loss, or mortality. Hemocompatibility of dressings that contact flowing blood or bleeding wound beds is assessed under ISO 10993-4, with hemolysis testing (direct contact and extract methods) being the most common endpoint; a hemolysis rate below 5% is generally considered acceptable. Complement activation and coagulation endpoints may be added for advanced hemostatic dressings.

Chemical Characterization and Toxicological Risk Assessment

Modern biological evaluation increasingly relies on chemical characterization per ISO 10993-18: extracts are analyzed by GC-MS, LC-MS, ICP-MS (particularly for silver-containing and other metal-impregnated dressings), and related techniques to identify extractables and leachables. Identified compounds are then evaluated through a toxicological risk assessment per ISO 10993-17, comparing estimated patient exposure against health-based exposure limits. This approach can scientifically justify waiving certain biological tests and is now expected by major regulators and notified bodies.

Applications

Biocompatibility test data for medical dressings serve several purposes across the product lifecycle:

• Regulatory submissions — supporting 510(k) premarket notifications and IDE submissions to the US FDA, CE technical documentation under EU MDR 2017/745, registration dossiers with China NMPA under GB/T 16886, and approvals in Japan, Canada, and other markets.
• Design and development — screening candidate polymers, adhesives, hydrocolloid formulations, and antimicrobial agents before committing to full-scale biological testing.
• Change control — re-evaluating biological safety after changes to raw material suppliers, formulations, manufacturing sites, or sterilization processes.
• Sterilization validation support — demonstrating that ethylene oxide sterilization leaves residues within ISO 10993-7 limits and that radiation sterilization does not generate cytotoxic degradation products.
• Post-market surveillance — supporting periodic safety updates, complaint investigations, and re-registration submissions.
• Biological safety documentation — forming the technical core of the ISO 10993-1 biological evaluation plan (BEP) and biological evaluation report (BER) within the ISO 14971 risk management file.

FAQ

What is the minimum biocompatibility test set for a wound dressing contacting breached skin for less than 30 days?

For most surface-contacting dressings applied to breached skin with prolonged contact, regulators expect at minimum cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), and irritation (ISO 10993-23), supported by chemical characterization. Acute systemic toxicity, material-mediated pyrogenicity, and subacute toxicity are added for large-area or long-duration products, and hemocompatibility is added for blood-contacting dressings.

Are in vitro irritation and sensitization tests accepted by regulators?

Yes, acceptance is expanding. RhE-based irritation testing is the preferred method under ISO 10993-23 and is broadly accepted by the FDA, EU notified bodies, and NMPA. For sensitization, defined in vitro approaches under OECD TG 442 are accepted in several jurisdictions, although many device programs still include an LLNA to strengthen the dataset. The testing strategy should always be confirmed with accredited third-party laboratories and the target market regulator in advance.

How many samples are needed and how long does testing take?

Cytotoxicity typically requires 3 to 10 sterile units and is completed within 2 to 4 weeks. RhE irritation studies need several units and take 2 to 4 weeks including extract preparation. LLNA studies require approximately 20 to 30 animals and 4 to 6 weeks, while GPMT studies take 8 to 10 weeks. Acute systemic toxicity takes 3 to 4 weeks, and full chemical characterization with toxicological risk assessment may take 8 to 12 weeks depending on the number of extractables identified.

Do antimicrobial dressings require additional testing?

Yes. Silver, iodine, PHMB, and other antimicrobial agents are intentionally released into the wound environment, so the biological evaluation must specifically address the released agent's systemic exposure, local effects, and cytotoxic impact. ICP-MS quantification of silver release and targeted toxicological assessment are commonly required, and the antimicrobial efficacy claim is evaluated separately from biocompatibility.

How do absorbable and biologically derived dressings differ in evaluation?

Collagen, alginate, chitosan, oxidized cellulose, and amniotic membrane products raise additional questions because the body absorbs or degrades them. The evaluation must address degradation products, absorption kinetics, and local tissue response, often requiring implantation testing under ISO 10993-6 and degradation studies under ISO 10993-13 or ISO 10993-15. In several jurisdictions, such products are classified as higher-risk devices requiring extended biological datasets.